NCT05123365

An Optimal Dose Finding Study of N-Acetylcysteine in Patients With Myeloproliferative Neoplasms

• Status: Recruiting
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 27 (estimated)
• Sponsor: University of California, Irvine · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This is a phase I/II study evaluating the optimal dose of N-acetylcysteine (N-AC) in patients with myeloproliferative neoplasms (MPN).

Detailed description

This is a phase I/II open-label clinical trial determining the optimal biological dose (OBD) of N-acetylcysteine in subjects with myeloproliferative neoplasms. These are subjects who have a diagnosis of essential thrombocythemia (ET), polycythemia vera (PV), or myelofibrosis (MF).

Conditions

• Myeloproliferative Neoplasm
• MPN
• Essential Thrombocythemia
• Polycythemia Vera
• Myelofibrosis

Interventions

Type	Name	Description
DRUG	N-Acetylcysteine	Given PO

Timeline

• Start date: 2022-01-03
• Primary completion: 2026-11-15
• Completion: 2026-11-15
• First posted: 2021-11-17
• Last updated: 2026-03-10

Locations

2 sites across 1 country: United States

Regulatory

• FDA-regulated drug study